How this instrument works
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is a prognostic score developed by Hoster and colleagues, published in Blood in 2008, from a pooled analysis of patients with advanced-stage mantle cell lymphoma enrolled in European clinical trials. It combines four routinely available variables — age, ECOG performance status, serum LDH relative to the local laboratory's upper limit of normal, and white blood cell count — into a single weighted score that stratifies patients into low-, intermediate-, and high-risk groups with meaningfully different overall survival in the original derivation cohort.
LDH is entered as a ratio to the lab's own upper limit of normal rather than as a raw value, because normal reference ranges for LDH vary between laboratories and assay methods; expressing it as a ratio lets the score be compared consistently across institutions. ECOG performance status is simplified in the formula to a binary split: 0-1 (largely unaffected by disease) versus 2-4 (more significant functional impairment), rather than using all five ECOG grades individually.
A detail specific to this score that is worth stating plainly: white blood cell count must enter the underlying formula in raw cells per microliter (cells/µL), not in the standard laboratory reporting unit of ×10⁹/L. This is a well-known point of clarification tied to a published Erratum to the original 2008 paper — the initial publication's WBC term, if applied using the everyday ×10⁹/L unit clinicians see on a lab report, understates the score. This calculator asks for WBC in the familiar ×10⁹/L unit (matching what appears on a standard complete blood count) and performs the required ×1000 conversion to cells/µL internally before calculating the score, so you should enter the number exactly as it appears on the lab report.
This is a specialist tool intended for hematologists and oncologists managing a confirmed mantle cell lymphoma diagnosis, most relevant to advanced-stage disease at the time treatment decisions are being made. It is not a screening or diagnostic instrument, and risk tier alone does not determine treatment — that depends on the full clinical picture, other prognostic factors (such as Ki-67 proliferation index, sometimes combined into the biological MIPI), and the treating center's protocol.
- Enter the patient's age in years.
- Select whether ECOG performance status is 2-4 (Yes) or 0-1 (No).
- Enter serum LDH in U/L, exactly as reported.
- Enter the testing laboratory's own upper limit of normal for LDH, in U/L — this varies by lab and assay.
- Enter the white blood cell count in the standard reporting unit, ×10⁹/L (for example, enter 7.5 for a WBC of 7.5 ×10⁹/L) — do not enter cells/µL directly; the calculator converts internally.
- Read the calculated WBC in cells/µL, the MIPI score, and the risk tier (1 = low, 2 = intermediate, 3 = high).
Worked example — three MIPI profiles across the risk tiers
A 65-year-old with ECOG 0-1 (not high), LDH 200 U/L against a lab ULN of 250 U/L, and a WBC of 8 ×10⁹/L (8,000 cells/µL after conversion): the score works out to about 5.831 — in the 5.7-to-under-6.2 band, so this scores as intermediate risk (tier 2).
A younger, lower-burden case — age 50, ECOG 0-1, LDH 150 against a 250 U/L ULN, WBC 5 ×10⁹/L (5,000 cells/µL): the score comes out to about 4.939, under the 5.7 threshold, so this scores as low risk (tier 1).
An older, higher-burden case — age 75, ECOG 2-4, LDH 400 against a 250 U/L ULN, WBC 20 ×10⁹/L (20,000 cells/µL): the score comes out to about 7.668, well above the 6.2 threshold, so this scores as high risk (tier 3). In the original Hoster et al. derivation cohort, median overall survival for the high-risk group was roughly 29 months, versus not-reached for the low-risk group over the study's follow-up.
Questions
Why does the WBC field ask for ×10⁹/L instead of cells/µL?
Because ×10⁹/L is the unit that appears on a standard complete blood count lab report, and that's what you should enter — for example, 7.5, not 7500. The MIPI formula itself was derived using raw cells/µL, and a published Erratum to the original 2008 Hoster et al. paper specifically clarified this unit requirement after it caused confusion. This calculator handles the ×1000 conversion internally, so entering the familiar lab-report number is correct; entering cells/µL directly into the WBC field would double-convert the value and produce an incorrect score.
Is the WBC unit issue really an official correction to the paper?
Yes — it is addressed by a published Erratum to Hoster et al., Blood 2008;111(2):558-565, clarifying the WBC unit convention required by the formula. This calculator's internal conversion follows that clarified convention (raw cells/µL) rather than the ×10⁹/L figure a clinician would read directly off a lab report.
What does the risk tier actually predict?
In the original derivation and validation cohorts, the three MIPI risk tiers were associated with meaningfully different overall survival in patients with advanced-stage mantle cell lymphoma — low risk had a substantially longer median survival than high risk. It is a prognostic index, describing likely disease course based on population data, not a treatment protocol by itself.
How is ECOG performance status simplified for this score?
The MIPI formula only distinguishes ECOG 0-1 from ECOG 2-4 as a single binary term, rather than weighting all five ECOG grades (0 through 4) separately. A patient with ECOG 2, 3, or 4 all contribute the same weighted amount to the score.
Why is LDH entered as a ratio to the lab's own upper limit of normal, instead of a raw value?
Different laboratories and assay platforms report different normal reference ranges for LDH. Expressing the patient's LDH as a ratio to their own lab's upper limit of normal (LDH ÷ ULN) normalizes for that variation, so the score means the same thing regardless of which lab ran the test.
Who should use this calculator?
Hematologists and oncologists managing a patient with a confirmed diagnosis of mantle cell lymphoma, typically at the point of considering treatment for advanced-stage disease. It is not intended for diagnosis, staging, or use by patients to interpret their own prognosis without clinical guidance.
Does a low-risk MIPI score mean treatment isn't needed?
No. MIPI is a prognostic tool describing expected disease course on average across a population, not a treatment-decision algorithm by itself. Treatment decisions depend on the full clinical picture — symptoms, disease extent, comorbidities, additional biomarkers such as Ki-67 proliferation index, and the treating center's protocols — which are outside the scope of this calculator.
References
- Hoster E, Dreyling M, Klapper W, et al. — A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565 (PMID 17962512)
- Erratum in Hoster et al. — A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(12):5761 (WBC unit clarification), doi:10.1182/blood-2008-04-151001
Read this first: This instrument computes a screening figure from population formulas — it is not a diagnosis, and it cannot see the whole picture a clinician can. Use it to inform a conversation, not to replace one.